#coinfection

The burden of viral and nonviral liver disease remains high even in the setting of hepatitis C microelimination.

People who are living with all three viruses have a greater likelihood of progressing to end-stage liver disease.

The risk of HCC fell further as cumulative antihistamine use rose in people with HBV, HCV or both.

Suppression of hepatitis B virus with antiviral treatment lowered the risk of hepatocellular carcinoma by 58%.

That’s the core message of an essay by Anthony S. Fauci, MD, director of the National Institute of Allergy and Infectious Diseases.

In the era of highly effective treatments for both viruses, HIV doesn’t speed the advancement of cirrhosis.

Researchers compared health outcomes among people with HIV, including those with and without hepatitis C.

Cure rates are high, but some young people already have advanced liver damage by the time they’re treated.

European and U.S. guidelines recommend that all those with cirrhosis undergo biannual screening for liver cancer.

People living with HIV are also facing cancer as they age.

The Office of HIV and AIDS Malignancy at the National Cancer Institute coordinates cancer and HIV research.

Four things you should know to be #HepAware.

A quick overview of our reporting on the 53rd International Liver Congress in Vienna

Better antiretrovirals have likely mitigated HIV’s effects on the risk of end-stage liver disease and liver cancer in those with hep C.

A research team has sought to address the critical lack of treatment guidelines for addressing HIV’s complex effects on aging.

A review of the major findings presented at the Annual Meeting of the American Association for the Study of Liver Diseases in San Francisco